NEW YORK, Jan. 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This analysis examines the historical and forecast performance for Novo Nordisk in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
* Gain insight into Novo Nordisk's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Strategic insight into the prospects for Novo Nordisk over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
* Benchmark Novo Nordisk's performance against key rivals in the prescription pharmaceutical sector* Assess the impact of the delay to Amylin and Eil Lilly's Bydureon on Novo Nordisk's Victoza sales performance out to 2015
To order this report:
Email: [email protected]
Intl: +1 805-652-2626